Rockwell Medical, Inc. to Present at Aegis Virtual Conference

Rhea-AI Summary

Rockwell Medical, a biopharmaceutical company specializing in iron deficiency treatments, will present at the Aegis Virtual Conference on February 23, 2022, from 1:30 to 2:00 PM ET. The company focuses on innovative therapies including its Ferric Pyrophosphate Citrate (FPC) platform, targeting iron deficiency in various patient populations, particularly those on hemodialysis. Recordings of this presentation will be available on their website from February 23 to 25, 2022. Rockwell Medical is also a leading supplier of hemodialysis concentrates in the U.S.

WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference, on Wednesday, February 23^rd at 1:30 - 2:00 PM ET.

A recording of the presentation will be posted to the Rockwell Medical website after the conference. The presentation will also be available by request to Aegis from February 23^rd to 25^th, 2022. To access the event, please download and import the following iCalendar (.ics) files to your calendar system: Aegis Virtual Conference Calendar.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. Rockwell Medical is also advancing its FPC platform by developing FPC for the treatment of iron deficiency anemia in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

FAQ

When is Rockwell Medical presenting at the Aegis Virtual Conference?

Rockwell Medical will present on February 23, 2022, from 1:30 to 2:00 PM ET.

What is the focus of Rockwell Medical's presentation at the conference?

The presentation will focus on Rockwell Medical's innovative treatments for iron deficiency and anemia management.

Where can I find the recording of Rockwell Medical's conference presentation?

The recording will be available on the Rockwell Medical website after the presentation.

What is Ferric Pyrophosphate Citrate (FPC) developed by Rockwell Medical?

FPC is a next-generation parenteral iron technology platform aimed at treating iron deficiency in various medical conditions.

What products has Rockwell Medical developed from the FPC platform?

Rockwell Medical has developed two FDA-approved therapies for patients undergoing hemodialysis from the FPC platform.